Stock BIOSTAR PHARMACEUTICALS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Biostar Pharmaceuticals Inc Stock Nasdaq

Equities

US0906782026

Pharmaceuticals

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Biostar Pharmaceuticals Inc
2023 Biostar Pharmaceuticals, Inc. Announces FDA Approval of Utidelone Injectable Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer CI
2023 Biostar Pharma, Inc. Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule CI

Financials (USD)

Sales 2015 27.13M Sales 2016 2.38M Capitalization 7.73M
Net income 2015 -25M Net income 2016 -5M EV / Sales 2015 0.33 x
Net Debt 2015 2.73M Net Debt 2016 2.15M EV / Sales 2016 4.14 x
P/E ratio 2015
-0.25 x
P/E ratio 2016
-1.17 x
Employees -
Yield 2015 *
-
Yield 2016
-
Free-Float 100%
More Fundamentals * Assessed data

Latest news about Biostar Pharmaceuticals Inc

Biostar Pharmaceuticals, Inc. Announces FDA Approval of Utidelone Injectable Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer CI
Biostar Pharma, Inc. Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule CI
Waiping Liu cancelled the acquisition of 16.2% stake in Biostar Pharmaceuticals, Inc. from Ronghua Wang. CI
Biostar Pharmaceuticals, Inc.(NasdaqCM:BSPM) dropped from NASDAQ Composite Index CI
Waiping Liu Discloses its Plans on Biostar Pharmaceuticals CI
Waiping Liu entered into share purchase agreement to acquire 16.2% stake in Biostar Pharmaceuticals, Inc. from Ronghua Wang for $0.67 million. CI
Biostar Pharmaceuticals, Inc. Announces Board Changes CI
Biostar Pharmaceuticals, Inc. Appoints Melissa Fan Chen as an Independent Member of the Board and the Chair of the Audit Committee CI
Biostar Pharmaceuticals, Inc. Announces Resignation of Leung King Fai as an Independent Director CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017 CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017 CI
Biostar Pharmaceuticals Seeks Acquisitions CI
Biostar Pharmaceuticals, Inc. cancelled the acquisition of Xianyang Yongsheng Health Products Co., Ltd. CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017 CI
Biostar Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2016 CI
More news

Managers and Directors - Biostar Pharmaceuticals Inc

Managers TitleAgeSince
Rong Hua Wang CEO
 Chief Executive Officer 69 07-03-26
Xiaojuan Zhai DFI
 Director of Finance/CFO - 17-02-04
Zheng Hong Wang COO
 Chief Operating Officer 43 12-02-29
Members of the board TitleAgeSince
Rong Hua Wang CEO
 Chief Executive Officer 69 07-03-26
Hai Peng Wu BRD
 Director/Board Member 66 07-06-30
Zhan Xiang Ma BRD
 Director/Board Member - 18-01-28
More insiders

Company Profile

Biostar Pharmaceuticals, Inc. (Biostar) is a holding company. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co., Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, manufactures and markets pharmaceutical products for various diseases and conditions in the People's Republic of China (PRC or China). The Company offers over-the-counter (OTC) products and prescription-based pharmaceuticals. The Company's products are sold in approximately 30 provinces in the PRC through a network of over 60 distributors and through approximately 230 sales people. The Company's products include XinAoxing Oleanolic Acid Capsule, Ganwang Compound Paracetamol Capsule, Tianqi Dysmenorrhea Capsule, Compound Paracetamol and Amantadine Hydrochloride Tablets, Deafness Tongqiao pills and Huangyangning Tablets.
Sector
Pharmaceuticals
More about the company

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.50% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.08% 550B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.33% 317B
ABBVIE INC. Stock AbbVie Inc.
+7.11% 292B
ASTRAZENECA PLC Stock AstraZeneca PLC
+3.26% 211B
NOVARTIS AG Stock Novartis AG
+0.78% 203B
PFIZER, INC. Stock Pfizer, Inc.
-10.37% 144B
AMGEN INC. Stock Amgen Inc.
-7.15% 141B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BSPM Stock
  4. Stock